PA.3 Study

A randomised placebo controlled study of OSI-774 (Tarcevaä) plus gemcitabine in patients with locally advanced, unresectable or metastatic pancreatic cancer.

Share

Trial Status

Completed

Cancer Type

Pancreatic Cancer

Aim

This trial will determine if a new drug, OSI-774 (TarcevaTM) given with chemotherapy will result in people living longer and with better quality of life.

Summary

When cancers of the pancreas are detected they have often spread to other parts of the body (metastases), or they return (recur) after surgery. The best treatment in this situation is chemotherapy with a drug called gemcitabine. As a result of chemotherapy, in many cases, the cancer will stop growing or get smaller for a time. In spite of chemotherapy, many of the cancers will start growing or return after a period of time.

Trial Status

Completed

Cancer Type

Pancreatic Cancer

Publication Reference

  1. Vickers MM, Lee C, Tu D, Wheatley-Price P, Parulekar W, Brundage MD, Moore MJ, Au H, O’Callaghan CJ, Jonker DJ, Ringash J, Goldstein D. Significance of baseline and change in quality of life scores in predicting clinical outcomes in an international phase III trial of advanced pancreatic cancer: NCIC CTG PA.3. Pancreatology 2016; 16(6): 1106-1112.
  2. Vickers MM, Powell ED, Asmis TR, Jonker DJ, Hilton JF, O’Callaghan CJ, Tu D, Parulekar W, Moore MJ. Comorbidity, age and overall survival in patients with advanced pancreatic cancer—results from NCIC CTG PA.3: a phase III trial of gemcitabine plus erlotinib or placebo. European Journal of Cancer 2012; 48(10): 1434–1442.

Conference Presentation Reference

Vickers M, Tu D, Lee C, Wheatley-Price P, Parulekar W, GBrundage M, Moore M, Au H, O’Callaghan C, Jonker D, Ringash J, Goldstein D. Significance of baseline quality of life scores in predicting clinical outcomes in an international phase III trial of advanced pancreatic cancer: NCIC CTG PA.3. American Society of Clinical Oncology Annual Meeting; 31 May–4 Jun 2013; Chicago. Journal of Clinical Oncology; 31 (suppl.): Abstract 4053.

Aim

This trial will determine if a new drug, OSI-774 (TarcevaTM) given with chemotherapy will result in people living longer and with better quality of life.

Summary

When cancers of the pancreas are detected they have often spread to other parts of the body (metastases), or they return (recur) after surgery. The best treatment in this situation is chemotherapy with a drug called gemcitabine. As a result of chemotherapy, in many cases, the cancer will stop growing or get smaller for a time. In spite of chemotherapy, many of the cancers will start growing or return after a period of time.

Principal Investigator

Conjoint Professor David Goldstein, Medical Onologist, Prince of Wales Hospital, NSW

Funding

OSI Pharmaceuticals Inc. (USA)